The April issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, features, and case reports, with topics ranging from hormonal therapy in hidradenitis suppurativa, private equity in dermatology, vitiligo and its associated comorbidities, novel topical products for facial dyschromia, and many more. Check out this month’s issue highlights straight from the JDD Editor’s desk:
A Comparative Analysis of Local Anesthetics: Injection Associated Pain and Duration of Anesthesia provides key takeaways of which compositions of anesthesia are the least painful solutions according to patients.
The Update on Hormonal Therapy in Hidradenitis Suppurativa reviews three databases and focuses on the roles of several hormonal therapies in treating HS.
The Double-Blind, Placebo-Controlled Study of Onabotulinumtoxin A for the Treatment of Hailey-Hailey Disease explores and provides results on the safety of injectable BTX-A for HHD.
A Systematic Review: Landscape of Private Equity in Dermatology From Past to Present calls on dermatologists to be patient advocates and to remain informed about private equity acquisitions of dermatology practices and the impact on patient care.
The Overview of the Immunobiology of Interleukin-23 Associated With Immune-Mediated Inflammatory Disorders. A Narrative Review explores the promising options of existing and emerging therapeutic biologics to treat IMIDs.
Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus explores the potential of this topical treatment as first-line monotherapy.
Drugs in Development for Chronic Spontaneous Urticaria provides insight into current treatments for CSU and the need for additional research to help reduce its burden on patients.
Patient Preferences in Topical Psoriasis Treatment surveys patients’ preferences and tolerances for use of topical solutions for this common inflammatory skin condition.
The Algorithm to Improve Patient Comfort and Treat Diabetes Mellitus-Related Xerosis educates and supports health professionals on how to best prevent complications during treatments.
The Effectiveness of Intralesional Platelet Rich Plasma in Recurrent Aphthous Stomatitis in Comparison With Triamcinolone Acetonide presents novel findings of how to safely treat and decrease the pain and frequency of associated ulcers.
A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia demonstrates a novel topical product’s safe and effective treatment with PATH-3 Technology.
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry analyzes a cohort of 1800+ adults to validate the correlation between patient-reported QoL scores with clinician assessment.
This case report examines the use of Dupilumab Induced Hair Regrowth in Alopecia Totalis and highlights its potential role in the treatment of resistant alopecia.
Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports discusses the use of other drugs in the GLP-1 agonist class as possible alternatives to treatments.
Although no drug has been approved for treatment, Open-Label Phase 2 Pilot Study of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) assesses the use of JAK inhibitors as treatment.
Pityriasis Alba in Pediatric Patients With Skin of Color addresses the lack of research investigating this condition and calls for further education and research to be conducted.
Having analyzed years’ worth of data, Brodalumab: 4-Year US Pharmacovigilance Report provides insights into this drug’s most common adverse effects and safety profile over long-term clinical trials.
Though a subject of controversy in the media, Self-Reported Long-Term Side Effects of Isotretinoin: A Case Series presents remote side effects that dermatologists must be aware of.
Shining a Light on the Vitiligo and Associated Comorbidities: What is the Evidence? stresses the importance that healthcare workers consider possible concurrent diseases when treating this condition.
Find more JDD Issue Highlights here.
